Loading...
OTCM
ATRX
Market cap0kUSD
May 02, Last price  
0.00USD
Jan 2017
-99.99%
Name

Adhera Therapeutics Inc

Chart & Performance

D1W1MN
P/E
0.00
P/S
—
EPS
0.33
Div Yield, %
—
Shrs. gr., 5y
36.23%
Rev. gr., 5y
76.78%
Revenues
0k
19,440,0001,847,0007,449,00028,490,00018,137,0002,609,00014,732,0002,460,0002,236,0004,217,0002,115,000500,000680,0000076,186252,000000
Net income
2m
P
-2,141,000-28,609,000-32,163,000-26,877,000-52,372,000-59,220,000-8,046,000-27,753,000-29,424,000-9,546,000-1,571,000-6,477,0003,337,000-837,143-6,219,348-16,754,957-12,640,000-5,540,000-7,784,0002,352,000
CFO
-1m
L+112.78%
-7,686,000-19,168,000-31,279,000-14,753,000-46,463,000-40,474,000-7,525,000-16,801,000-16,117,000-4,391,000285,000-4,779,000-2,165,000-522,314-1,260,685-9,611,433-8,738,000-588,000-665,000-1,415,000

Profile

Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
URL
https://adherathera.com/
IPO date
Apr 15, 1994
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
1,618
Unusual Expense (Income)
NOPBT
(1,618)
NOPBT Margin
Operating Taxes
(4,466)
Tax Rate
NOPAT
2,848
Net income
2,352
-130.22%
Dividends
(620)
Dividend yield
32.77%
Proceeds from repurchase of equity
5,054
BB yield
-267.12%
Debt
Debt current
8,585
Long-term debt
Deferred revenue
Other long-term liabilities
10,982
Net debt
8,553
Cash flow
Cash from operating activities
(1,415)
CAPEX
Cash from investing activities
Cash from financing activities
1,371
FCF
(1,947)
Balance
Cash
32
Long term investments
Excess cash
32
Stockholders' equity
(55,732)
Invested Capital
42,131
ROIC
7.44%
ROCE
11.90%
EV
Common stock shares outstanding
2,308
Price
0.82
-44.60%
Market cap
1,892
96.63%
EV
10,445
EBITDA
191
EV/EBITDA
54.69
Interest
3,153
Interest/NOPBT